CAI’s Post

#Mabwell (Shanghai) Bioscience Co., Ltd.and #Innobic (Asia) Enter into Commercial Collaboration in the #thailand Market #Mabwell (688062.SH), an innovative biopharmaceutical company with a fully integrated industry layout, has announced its licensing and supply agreement with the Thai pharmaceutical company Innobic (Asia) ("Innobic"). This collaboration involves the registration and commercialization of #Mabwell 's products in Thailand, one of the member countries of the Pharmaceutical Inspection Cooperation Scheme (PIC/S). Innobic is a wholly-owned subsidiary of PTT, the largest state-owned company by market value listed on the Stock Exchange of Thailand, formerly known as the Petroleum Authority of #thailand . #BIO Partnering offers a unique opportunity to engage with facilitating a total of 10,000 pre-scheduled meetings. Learn more and hashtag #register here: https://lnkd.in/eDxy-Hs2 800  #biotech companies 500  #investment Institutions 200  #pharmaceutical Companies 100  #multinationalcompany Corporations/Overseas Institutions 200  #suppliers

Did you know that ionic charge can affect antibody-target binding? Learn how Twist helped a leading pharmaceutical company precisely interrogate key residues involved in both target recognition and antibody charge by synthesizing combinatorial variant libraries. Twist Bioscience, Lucy X., #antibody #antibodies #DNA #TwistBiopharmaSolutions

💻 On-demand webinar to help you advance oligonucleotide drug development You'll learn about the techniques for phosphoramidite synthesis, selection, and evaluation for the development of oligonucleotide drugs. The webinar discusses: ✅Optimizing phosphoramidites for oligonucleotide therapeutic development and manufacturing ✅ Identifying phosphoramidite impurities and their potential impacts on oligonucleotide therapeutics #webinar #drugdevelopment

Are you looking to expand your knowledge of oligonucleotide bioanalysis? This is your last chance to register for our webinar in partnership with SCIEX. Discover more about drug development strategies for the bioanalytical analysis of oligonucleotide therapies by registering today >>> https://bit.ly/48D7y3c

🔍 Join Abzena to explore how key technologies and processes can expedite early-phase #biologics to the clinic and beyond. Learn about the latest in mammalian cell-based biologics for #MonoclonalAntibodies, fusion proteins, antibody fragments, bispecifics, and ADCs. 🔬 Discover strategies for creating robust, flexible, and cost-effective production processes to meet the rising demand for these efficacious drugs. The expert speakers will cover the impact of fully integrated end-to-end single-use technologies, advances in cell line development, and new purification platforms. Through case studies, see how Abzena uses Sartorius’ technologies and a quality by-design approach to rapidly develop and implement processes in a CDMO setting. ➡️ REGISTER HERE: https://buff.ly/3ywKyoS 🌟 Expert speakers: Dennis Yoon Priyanka Gupta #DrugDevelopment #CommercialManufacturing #CDMO #BiologicsManufacturing

Recap of Biologics 2024:  We had a great time discussing and learning about new innovations and technologies in peptide therapeutics.  Some highlights: Vera D'Aloisio participated in the Panel Discussion: Sustainability In Tides Chemistry: An Integrated Approach Michael Pennington presented “Peptide Synthesis Strategies for Production of Commercial GLP-1 Agonists". -with Georgina Balcells, Mikael Moissant AmbioPharm has additional industry events in March where we will be speaking and available to showcase our peptide manufacturing and development services. 🗓 Upcoming March Conferences: DCAT Week | March 18-21 | NYC, NY USA TIDES Asia | March 19-21 | Kyoto, Japan https://lnkd.in/eH48ZARU #OGBiologics #Biologics24 #cgmp #peptides #cdmo #drugdevelopment #peptidesynthesis #peptidetherapeutics #biologicsuk #sustainability

We continue to feature the most popular and impactful articles published in 2023 in our journal, Antibody Therapeutics (2022 CiteScore: 6.4). The title of the 9th article we’d like to feature is “Comparability strategy and demonstration for post-approval production cell line change of a bevacizumab biosimilar IBI305”. Post-approval cell line changes of commercial biologics are very rare in biopharmaceutical industry in the world. This article represents the first report of comparability exercise for the post approval production cell line change in China, following a QbD approach with tier-based quality attribute evaluation and risk assessment. It is also the first paper with the first author from China’s CDE/NMPA-National Medical Products Administration published in our journal. Our journal has published at least three articles from FDA in the past 6 years. Other co-authors and co-corresponding authors are from Innovent Biologics.    Antibody Therapeutics (2022 CiteScore: 6.4) is the official journal of Chinese Antibody Society (CAS), a non-profit, non-government global professional organization with focus upon antibody-based therapeutics. CAS’s 2024 Annual Conference will take place in Cambridge, MA, USA, on Saturday, May 11, 2024. The theme of this conference is “Beyond Borders: Advancements in Antibody-Based Therapeutics in Uncharted Territories". You are welcome to register for the conference right NOW via the following link. https://lnkd.in/ecmFPA4v   #biologics #antibody #antibodies #antibodydiscovery #antibodytherapeutics #mab #mabs #biosimilar #biosimilars #cellline #cellinedevelopment #annualmeeting #annualconference

The landscape of antibody drug conjugates is dynamic and ever-changing. In a recent article with Drug Target Review, our resident experts Nicolas Camper, Campbell Bunce PhD MBA Bunce and Johanna Midelet present unmatched knowledge of how the therapy is evolving and provide an insight into how the future of ADCs could look. Be sure to check it out here: https://lnkd.in/eF_87s4g Oh, and also, in case you didn't know already, our bioconjugation process development group is purpose built for the optimization and scale-up of your ADCs and bioconjugates, so be sure to also check out how we can support your next ADC project here: https://lnkd.in/gbFqAZ34 #CDMO #Pharma #Antibodies

Curia will be in Boston for the Next-Generation Conjugates Summit—will you? If so, join our poster presentation titled 'Studies on Conjugates of Hydroxyl-Bearing Payloads: A Silyl Ether Strategy with Potential for Hydrolytic or Assisted Cleavage', presented by David Manning, Ph.D, Associate Research Fellow with Curia. Along with Dr. Manning, our other experts Roger Wong, Ph.D., MBA (Head of Business Development, Biologics Discovery), and Emily Wang (Business Development, Biologics Discovery), will be available to discuss your bioconjugate drug development and other research projects. From drug discovery to GMP manufacturing, learn how Curia can help accelerate your novel conjugate into and through the clinic. Ready to schedule a meeting? Email Roger [email protected] or Emily [email protected] #CDMO #biologics #mAb #RecombinantProteins #mRNA #Therapeutics #smallmolecules #drugdiscovery #adc

Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations, full article here: https://lnkd.in/d3u7m4Eq thanks to Carole Nicco Ryan Guest BIOSENIC S.A. eXmoor Pharma Thanks also to Cynthia Challener and Pharmaceutical Technology “There is a clear unmet need for the discovery and development of novel cryoprotectants that can either replace or reduce the required amounts of current gold standards formulated to protect and treat challenging sample types such as MSCs and, even more, iPSC multicellular systems. This multivariate problem is complex, with multiple mechanisms of damage to be addressed and subtle differences between cell types and freezing methods. Combining high-throughput testing with iterative computational algorithms is key to optimizing protocols and excipient formulations to preserve emerging cell-based therapies,” Nicco comments. #excipients #cryopreservation #cellandgenetherapy #formulationdevelopment #stemcells #ipscs